Results 81 to 90 of about 34,512 (245)

Correlation of microRNAs-10b/21/34a expression levels with IDH1-mutation status in patients with glioblastoma [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Isocitrate dehydrogenase (IDH) mutations play a significant role in gliomagenesis. Specific microRNAs, such as microRNA-10b and microRNA-21, act as oncogenic microRNAs, whereas microRNA-34a acts as a tumor suppressor in ...
Stepanović Aleksandar, Petrović Nina, Arsenijević Tatjana, Nikitović Marina   +3 more
doaj   +1 more source

Mutational status of IDH1 in uveal melanoma

Experimental and Molecular Pathology, 2016
Uveal (intraocular) melanoma is an uncommon malignancy that comprises a small percentage of all melanoma cases. While many uveal melanomas harbor mutations in the BRCA-Associated Protein 1 (BAP1) gene, the genetics of non-BAP1 associated tumors are not completely understood.
Patrick J. Cimino, Yungtai Kung, Joshua I. Warrick, Shu-Hong Chang, C. Dirk Keene   +4 more
openaire   +3 more sources

IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. [PDF]

PLoS ONE, 2016
TETs (TET1/2/3) play critical roles in multi cellular processes through DNA demethylation driven by oxidation of DNA 5mdC to 5hmdC. Interestingly, recent studies indicated that TETs also oxidate RNA 5mC to 5hmC.
Qiang Xu, Kai Wang, Lina Wang, Yuting Zhu, Guangyu Zhou, Dan Xie, Qingkai Yang   +6 more
doaj   +1 more source

Novel IDH1-Targeted Glioma Therapies

CNS Drugs, 2019
Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic mechanisms of oncogenesis ...
Trang T. T. Nguyen, Markus D. Siegelin, Enyuan Shang, Georg Karpel-Massler   +3 more
openaire   +3 more sources

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, EarlyView.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

Haematologica, 2019
Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known.
Chi Young Ok, Sanam Loghavi, Dawen Sui, Peng Wei, Rashmi Kanagal-Shamanna, C. Cameron Yin, Zhuang Zuo, Mark J. Routbort, Guilin Tang, Zhenya Tang, Jeffrey L. Jorgensen, Rajyalakshmi Luthra, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo, L. Jeffrey Medeiros, Sa A. Wang, Keyur P. Patel   +17 more
doaj   +1 more source

Oxidative phosphorylation at the crossroads of cancer: Metabolic orchestration, stromal collusion, and emerging therapeutic horizons

Interdisciplinary Medicine, EarlyView.
Although most cancer cells rely on aerobic glycolysis, Oxidative phosphorylation (OXPHOS) remains essential for their survival, proliferation, and metastasis. With the emergence of OXPHOS‐targeted drugs, its therapeutic potential is becoming increasingly evident.
Keke Chen, Bo Wang, Hongying Shu, Jianxin Lyu, Wei Cui, Hezhi Fang   +5 more
wiley   +1 more source

Prognostic significance of HIF1-α immunohistochemical expression in gliomas and it's relation to IDH1 mutation status

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Gliomas are the commonest primary adults’ brain tumors. Hypoxia performs an essential role in gliomas’ initiation as well as progression through hypoxia inducible factor (HIF-1α) activation, which could serve as a promising target in treatment
Eman Ahmed Abd Elmaogod, Sahar Aly Daoud, Zahraa Mohammed Mostafa, Ebtehal Mohamed Mostafa Mahmoud   +3 more
doaj   +1 more source

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas [PDF]

Cancer Research, 2013
Abstract Point mutations at Arg132 of the cytoplasmic NADP+-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the “oncometabolite” D-2-hydroxyglutarate (D-2HG). The mutated IDH1 allele is usually associated with a wild-type IDH1 allele (heterozygous) in cancer.
Jin, Genglin, Reitman, Zachary J, Duncan, Christopher G, Spasojevic, Ivan, Gooden, David M, Rasheed, B Ahmed, Yang, Rui, Lopez, Giselle Y, He, Yiping, McLendon, Roger E, Bigner, Darell D, Yan, Hai   +11 more
openaire   +3 more sources